{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T18:29:03Z","timestamp":1784658543739,"version":"3.55.0"},"reference-count":46,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2020,1,14]],"date-time":"2020-01-14T00:00:00Z","timestamp":1578960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Department of Health Research, Government of India","award":["R.11011\/04\/208"],"award-info":[{"award-number":["R.11011\/04\/208"]}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The effect of baseline resistance\u2010associated substitutions (RAS) on the sustained virologic response at 12\u00a0weeks (SVR12) among chronic hepatitis C (CHC) patients receiving the second generation, pan\u2010genotypic glecaprevir\/pibrentasvir (G\/P) regimen is unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To assess the effect of RAS on the SVR12 in CHC patients treated with G\/P regimen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The EMBASE, MEDLINE and Cochrane central register of controlled trials databases were searched for relevant studies published before 1 March 2019. The principal outcome was to compare the SVR12 in CHC patients with and without baseline RAS, particularly in genotype\u20101, genotype\u20103 and direct\u2010acting anti\u2010virals (DAAs) failure patients. The outcomes were pooled using a random\u2010effects model and odds ratio (OR) was calculated. The risk of bias was assessed using the Cochrane risk of bias tools for randomised and nonrandomised interventional studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After initially identifying 410 studies, 3302 patients from 17 studies were included. Among 50 cases of virologic failures, 48% had genotype\u20103 infection, 44% genotype\u20101 infection and 36% DAA\u2010failure patients. Baseline RAS were present in 44(88%) patients. The most common NS5a and NS3 mutations were Y93H and A166S respectively. The odds of SVR12 were significantly reduced in patients with any baseline RAS (NS3 and\/or NS5a) (OR 0.32, 95%C I[0.15, 0.65], <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u00a0=\u00a00%) and NS5a substitutions (OR 0.36, 95%CI [0.18,0.73]). The impact of RAS on SVR12 was significant among genotype\u20103 patients, but not among genotype\u20101 or DAA\u2010failure cases. The presence of Y93H and A30K mutations significantly impacted SVR12 rates in genotype\u20103 patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Baseline NS3 or NS5a RAS, especially the NS5a substitutions\u2014A30K, Y93H, decrease the odds of achieving SVR12 in genotype\u20103 CHC patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/apt.15633","type":"journal-article","created":{"date-parts":[[2020,1,15]],"date-time":"2020-01-15T11:53:06Z","timestamp":1579089186000},"page":"490-504","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Systematic review with meta\u2010analysis: impact of baseline resistance\u2010associated substitutions on the efficacy of glecaprevir\/pibrentasvir among chronic hepatitis C patients"],"prefix":"10.1111","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9094-1071","authenticated-orcid":false,"given":"Achintya D.","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Cleveland Clinic Cleveland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souvik","family":"Maitra","sequence":"additional","affiliation":[{"name":"Department of Anaesthesia All India Institute of Medical Sciences New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nita","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology All India Institute of Medical Sciences New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payal","family":"Tyagi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology All India Institute of Medical Sciences New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anzar","family":"Ashraf","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology All India Institute of Medical Sciences New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5136-4865","authenticated-orcid":false,"given":"Ramesh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology All India Institute of Medical Sciences Patna India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1247-437X","authenticated-orcid":false,"family":"Shalimar","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology All India Institute of Medical Sciences New Delhi India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,1,14]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30181-9"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-014-0145-y"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.4103\/0971-5916.182624"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2018.01.004"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27259"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.2174\/1574887114666190306154650"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.01.007"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.06.002"},{"key":"e_1_2_7_10_1","unstructured":"AASLD\u2010IDSA.HCV resistance primers. Recommendations for testing managing and treating hepatitis C.https:\/\/www.hcvguidelines.org\/evaluate\/resistance. Accessed April 10 2019."},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01249-18"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01249-18"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535"},{"key":"e_1_2_7_14_1","unstructured":"SinghAD SinghN TyagiP AnzarA Shalimar.Impact of baseline resistance\u2010associated substitutions on treatment response in patients with Hepatitis C virus infection receiving pan\u2010genotypic directly acting antivirals. PROSPERO 2019 CRD42019126281.http:\/\/www.crd.york.ac.uk\/PROSPERO\/display_record.php?ID=CRD42019126281. Accessed May 12 2019."},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb1609216"},{"key":"e_1_2_7_16_1","unstructured":"HigginsJ GreenS.Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011.http:\/\/handbook.cochrane.org. Accessed January 18 2019."},{"key":"e_1_2_7_17_1","first-page":"29","article-title":"A revised tool for assessing risk of bias in randomized trials","volume":"10","author":"Higgins JP","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919"},{"key":"e_1_2_7_19_1","first-page":"MR000033","article-title":"Industry sponsorship and research outcome","volume":"2","author":"Lundh A","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_20_1","unstructured":"Visual Rx.Dr Chris Cates\u2019 EBM website.http:\/\/www.nntonline.net\/visualrx\/. Accessed November 19 2019."},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-017-1396-0"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-017-1391-5"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29510"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy220"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30341-8"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.09.027"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25278"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29081"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704053"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.039"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30496-6"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702417"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29671"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30046"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.07.020"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-018-1520-9"},{"key":"e_1_2_7_37_1","first-page":"402A","article-title":"Real\u2010world efficacy of glecaprevir plus pibrentasvir for patients with HCV with or without prior daa therapies: Evaluation by deep sequencing for HCV strains with NS5ARAS","volume":"68","author":"Uemura H","year":"2018","journal-title":"Hepatology"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12870"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.6"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0817-y"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.07.005"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2017.06.009"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2018.1544492"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.09.011"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02558-16"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512612"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.01.031"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.15633","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.15633","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T03:46:35Z","timestamp":1694058395000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.15633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,14]]},"references-count":46,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["10.1111\/apt.15633"],"URL":"https:\/\/doi.org\/10.1111\/apt.15633","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,14]]},"assertion":[{"value":"2019-08-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}